These data show that Cet-BPD-based PDP combined with AH23848 significantly inhibited ovarian cancer cell migration compared to both Cet-BPD-based PDP or AH23848 alone, demonstrating the superior potency of this combination regimen. Here, PDP1 is linked to ovarian carcinoma.